We conclude that a substantial proportion of relapsed/refractory B-cell and T-cell non-Hodgkin lymphomas and nearly all classic Hodgkin lymphomas overexpress PD-L1 protein, implying a potential utility of checkpoint blockade therapy in these difficult to treat diseases. Here, CD274 is linked to T-cell non-Hodgkin lymphoma.